p38 MAPK
The p38 MAPK family consists of highly conserved proline-directed serine-threonine protein kinases that are activated in response to a number many growth factors, cytokines, and chemotactic substances, such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), PDGF, TNF, interleukins, lipopolysaccharide (LPS) and formyl-methionyl-leucyl-phenylalanine (fMLP). It is well known that p38 is involved in inflammation, apoptosis, cardiomyocyte hypertrophy and cell differentiation.
The p38 MAPK family is composed of four proteins: p38α (encoded by the gene Mapk14), p38β (Mapk11), p38γ (Mapk12), and p38δ (Mapk13). Their coding genes have a distinct tissue distribution and they appear differentially expressed, being Mapk14 the most highly expressed. p38 MAPKs are substrates for three MAP2K (MKK6, MKK3, and MKK4). The contribution of each of these MAP2K to p38 MAPKs activation depends on the stimulus and the cell type. The MAP3Ks that lead to p38 MAPKs activation are ASK1, DLK1, TAK1, TAO1, TAO2, TPL2, MLK3, MEKK3, MEKK4, and ZAK1.
p38 MAPK Isoform Specific Products
All Product Categories
-
p38 MAPK Inhibitors
(821)
View all products
-
p38 MAPK Agonists
(6)
View all products
-
p38 MAPK Antagonists
(2)
View all products
-
p38 MAPK Activators
(216)
View all products
-
p38 MAPK Modulators
(20)
View all products
-
p38 MAPK p53 Inhibitors
(2)
View all products
-
p38 MAPK Inducers
(11)
View all products
-
p38 MAPK Degraders
(3)
View all products
-
p38 MAPK Control
(1)
View all products
-
p38 MAPK Ligands
(2)
View all products
-
AKT Serine/Threonine Kinase 1 (AKT1) Proteins
(3)
View all products
-
p38 MAPK Related Products (1175)
Related Products (1175)
-
Recombinant Proteins (3)
-
Antibodies (20)
-
p38 MAPK Isoform Comparison
-
7-Ketocholesterol (Standard)
0 Images7-Ketocholesterol (Standard) is the analytical standard of 7-Ketocholesterol. This product is intended for research and analytical applications. 7-Ketocholesterol is an oxidation product of cholesterol, widely present in atherosclerotic plaques, and has a stronger atherogenic effect than cholesterol. 7-Ketocholesterol can inhibit the rate-limiting enzymes involved in bile acid and cholesterol synthesis, such as cholesterol 7α-hydroxylase and HMG-CoA reductase. 7-Ketocholesterol exhibits pro-inflammatory effects both in vivo and in vitro and can induce cell apoptosis (apoptosis).
-
ZINC-1000507824
0 ImagesCat. No.: HY-181963ZINC-1000507824 is a non-covalent reversible RNA cytosine-5 methyltransferase NSUN2 inhibitor. ZINC-1000507824 targets the SAM cofactor binding pocket of NSUN2 and forms stable NSUN2-ligand complexes. ZINC-1000507824 destabilizes oncogenic mRNAs encoding PI3K/AKT and MAPK/ERK pathway components, attenuates growth signals, reduces proliferative drive, and restores therapy sensitivity in cancer cells. ZINC-1000507824 can be used for the research of NSUN2-driven malignancies.
-
p38 MAP Kinase-IN-4
0 ImagesCat. No.: HY-183531CAS No.: 1228148-61-5p38 MAP Kinase-IN-4 is a p38α MAPK inhibitor with an IC50 of 40.5 nM. p38 MAP Kinase-IN-4 is applicable to inflammation-related research.
-
O6-Benzylguanine (Standard)
0 ImagesO6-Benzylguanine Standard is the analytical standard of O6-Benzylguanine (HY-W002585). This product is intended for research and analytical applications. O6-Benzylguanine is an orally active, blood-brain barrier-penetrant inhibitor of O6-methylguanine-DNA methyltransferase (MGMT/AGT). O6-Benzylguanine modulates p53 and its downstream p21 and cyclins to induce cell cycle arrest and apoptosis, and on the other hand activates mTORC1/MAPK and other signaling pathways to induce cellular senescence by inhibiting intracellular MGMT. O6-Benzylguanine is used in research related to various tumors, cellular senescence, and vascular smooth muscle dysfunction.
-
Iroxanadine hydrochloride
0 ImagesCat. No.: HY-19399DCAS No.: 276690-59-6Synonyms: (-)-BRX 005 hydrochloride; (-)-BRX 235 hydrochlorideIroxanadine (BRX 005) hydrochloride is a vasculoprotector. Iroxanadine is a p38 kinase and HSP protein dual activator. Iroxanadine hydrochloride has the potential for atherosclerosis and vascular diseases research.
-
Gamma-glutamylcysteine ammonium
0 ImagesCat. No.: HY-113402BSynonyms: γ-Glu-Cys ammoniumGamma-glutamylcysteine ammonium (γ-Glu-Cys ammonium) is an orally active, blood-brain barrier permeable dipeptide. Gamma-glutamylcysteine ammonium activates AMPK, SIRT1, IL-4/STAT6, AC/cAMP/PI3K, IGF-1R/IRS1/PI3K, and Nrf2 signaling pathways; it inhibits NF-κB, JAK1/STAT1/3, MAPKs, cadmium-induced p38 MAPK, JNK, and PI3K/Akt signaling pathways. Gamma-glutamylcysteine ammonium regulates macrophage polarization, modulates the trafficking of CD36 and GLUT4, induces glutathione synthesis, improves metabolic dysfunction, reduces lipid deposition, ameliorates glucose homeostasis, inhibits apoptosis (Apoptosis), stabilizes mitochondria, suppresses lipid peroxidation, iron accumulation and ferroptosis (Ferroptosis), reduces ds-HMGB1 levels, reverses mechanical hyperalgesia, and alleviates hepatic lipid droplet formation. Gamma-glutamylcysteine ammonium is applicable to research related to inflammatory bowel disease, type 2 diabetes, cadmium-induced neurotoxicity, Alzheimer's disease, cerebral ischemia/reperfusion injury, neuropathy, and alcoholic liver disease.
-
SKF-86002 (Standard)
0 ImagesSKF-86002 (Standard) is the analytical standard of SKF-86002. This product is intended for research and analytical applications. SKF-86002 is an orally active p38 MAPK inhibitor, with anti-inflammatory, anti-arthritic and analgesic activities. SKF-86002 inhibits lipopolysaccharide (LPS)-stimulate human monocyte IL-1 and TNF-α production (IC50 = 1 μM). SKF-86002 inhibits lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid.
-
Hypaphorine (Standard)
0 ImagesHypaphorine is an indole found in Caragana korshinskii. Hypaphorine has neurological and glucose-lowering effects. Hypaphorine prevents Lipopolysaccharides (LPS) (HY-D1056)-mediated acute lung injury (ALI) and proinflammatory response via inactivating the p38/JNK signaling pathway by upregulating DUSP1.
-
PMK1-IN-1
0 ImagesCat. No.: HY-179252PMK1-IN-1 (compound H17) is a potent PMK1 inhibitor. PMK1-IN-1 shows superior inhibitory effects against M. oryzae by targeting the pathogenicity MAPK MoPMk1, with an IC50 of 0.42 μM. PMK1-IN-1 exhibits effects in vivo similar to those of Carbendazim (HY-13582). PMK1-IN-1 can be used for rice blast disease research.
-
RWJ-67657 (Standard)
0 ImagesCat. No.: HY-15505RCAS No.: 215303-72-3Synonyms: JNJ 3026582 (Standard)RWJ-67657 (Standard) is the analytical standard of RWJ-67657. This product is intended for research and analytical applications. RWJ-67657 (JNJ 3026582) is an orally active and selective p38α and p38β MAPK inhibitor with IC50s of 1 and 11 μM, respectively. RWJ-67657 displays no activity at p38γ and p38δ, and exhibits cardio protective effect. Anti-inflammatory and anti-tumor activity.
-
p38 MAPK-IN-11
0 ImagesCat. No.: HY-183530CAS No.: 152121-51-2p38 MAPK-IN-11 is a CSBP (p38 MAPK) kinase inhibitor with IC50 values of 0.15 μM (binding activity) and 0.21 μM (inhibitory activity). p38 MAPK-IN-11 shows weak inhibitory activity against PKCα kinase, with an IC50 of 7.6 μM. p38 MAPK-IN-11 inhibits the production of IL-1. p38 MAPK-IN-11 also acts as a β-lactam antibiotic potentiator, but has no antibacterial activity itself.
-
p38 MAP Kinase-IN-1
0 ImagesCat. No.: HY-171275CAS No.: 815595-27-8p38 MAP Kinase-IN-1 (Compound 4) is the inhibitor for p38, and can be used for inflammation and auto-immune responses related research.
-
JH-I-25
0 ImagesCat. No.: HY-138834CAS No.: 1042673-20-0JH-I-25 is an orally active IRAK1 and IRAK4 inhibitor. JH-I-25 inhibits LPS-induced IRAK4 phosphorylation, IRAK1 degradation, MAPK activation, and the expression of proinflammatory cytokines TNF-α and IL-6 in lung tissues. JH-I-25 improves the survival rate of LPS-induced septic mice and serves as an IRAK4 recruiter in the design of proteolysis-targeting chimeric molecules. JH-I-25 can be used in research related to diffuse large B-cell lymphoma, Waldenström's macroglobulinemia, septic shock, rheumatoid arthritis, atherosclerosis, Alzheimer's disease, acute lung injury, sepsis, and psoriasis.
-
SKLB646
0 ImagesCat. No.: HY-164530CAS No.: 1970149-05-3SKLB646 is an orally active multi-target kinase inhibitor. SKLB646 shows significant inhibitory effects on SRC and VEGFR2 with IC50 values ??of 0.002 μmol/L and 0.012 μmol/L, respectively. SKLB646 also shows significant inhibitory effects on B-Raf and C-Raf with IC50 values ??of 0.022 μmol/L and 0.019 μmol/L, respectively. SKLB646 inhibits the activation of the SRC signaling pathway and blocks the MAPK signaling pathway by inhibiting Raf kinase. In addition, SKLB646 can inhibit the proliferation, migration and invasion of human umbilical vein endothelial cells (HUVEC) to inhibit tumor-induced angiopoietic formation. SKLB646 shows significant anti-proliferative and anti-survival activities against triple-negative breast cancer (TNBC) cell lines.
-
L-Quebrachitol (Standard)
0 ImagesL-Quebrachitol is a methoxy analog of inositol that can be isolated from plants. L-Quebrachitol has free-radical scavenging, gastroprotection, anti-platelet aggregation and anti-diabetic activity. L-Quebrachitol promotes osteoblastogenesis by uppregulation of BMP-2, runt-related transcription factor-2 (Runx2), MAPK (ERK, JNK, p38α), and Wnt/β-catenin signaling pathway.
-
p-Cresol sulfate-d4 potassium
0 ImagesCat. No.: HY-W654121Synonyms: p-Tolyl sulfate-d4 potassium
-
7-Acetoxycoumarin
0 ImagesCat. No.: HY-N20744CAS No.: 10387-49-2Synonyms: Acetylumbelliferone7-Acetoxycoumarin (Acetylumbelliferone) is an anti-inflammatory inhibitor with antibacterial and amoebicidal activities. 7-Acetoxycoumarin reduces the phosphorylation levels of ERK, JNK, NF-κB and p38 MAPK. 7-Acetoxycoumarin downregulates the protein and mRNA expression levels of iNOS and COX-2. 7-Acetoxycoumarin inhibits the production of IL-1β, IL-6, TNF-α, NO and PG2. 7-Acetoxycoumarin reduces the degradation of IκBα. 7-Acetoxycoumarin can be used in studies related to amoebiasis and Bacillus lentus infection.
-
Sorafenib tosylate (Standard)
0 ImagesSynonyms: Bay 43-9006 tosylate (Standard)Sorafenib (tosylate) (Standard) (Bay 43-9006 (tosylate) (Standard)) is the analytical standard of Sorafenib (tosylate) (HY-10201A). This product is intended for research and analytical applications. Sorafenib (Bay 43-9006) tosylate is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib tosylate induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib tosylate inhibits tumor growth and metastasis in mouse and rat models. Sorafenib tosylate can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma.
-
Bilobetin (Standard)
0 ImagesBilobetin (Standard) is the analytical standard of Bilobetin. This product is intended for research and analytical applications. Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity.
